AR050293A1 - Polipeptidos de interleuquina-15 mutante - Google Patents

Polipeptidos de interleuquina-15 mutante

Info

Publication number
AR050293A1
AR050293A1 ARP050103371A ARP050103371A AR050293A1 AR 050293 A1 AR050293 A1 AR 050293A1 AR P050103371 A ARP050103371 A AR P050103371A AR P050103371 A ARP050103371 A AR P050103371A AR 050293 A1 AR050293 A1 AR 050293A1
Authority
AR
Argentina
Prior art keywords
mutant
polypeptides
polypeptide
interleuquine
glutamine residues
Prior art date
Application number
ARP050103371A
Other languages
English (en)
Original Assignee
Moll Tomas
Zheng Xin Xiao
Strom Terry B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moll Tomas, Zheng Xin Xiao, Strom Terry B filed Critical Moll Tomas
Publication of AR050293A1 publication Critical patent/AR050293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Composiciones que incluyen dichos polipéptidos, así como método para obtenerlos entre otros, el polipéptido IL-15 mutante está unido a un polipéptido heterologo. Usos de los polipéptidos IL-14 mutantes, por ejemplo, en la supresion de respuestas inmunes. Reivindicacion 1: Un polipéptido de interleuquina-15 (IL-15) mutante, caracterizado porque comprende una IL-15 natural que contiene una mutacion por supresion de uno o más de los primeros 48 residuos de aminoácidos de la secuencia senal y una mutacion por sustitucion de uno de los residuos de glutamina correspondiente a los residuos de glutamina en las posiciones 101 y 108 de la SEQ ID Ns: 1.
ARP050103371A 2004-08-11 2005-08-11 Polipeptidos de interleuquina-15 mutante AR050293A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60104204P 2004-08-11 2004-08-11
US60047804P 2004-08-11 2004-08-11

Publications (1)

Publication Number Publication Date
AR050293A1 true AR050293A1 (es) 2006-10-11

Family

ID=35839987

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103369A AR050693A1 (es) 2004-08-11 2005-08-11 Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.
ARP050103371A AR050293A1 (es) 2004-08-11 2005-08-11 Polipeptidos de interleuquina-15 mutante

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050103369A AR050693A1 (es) 2004-08-11 2005-08-11 Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.

Country Status (4)

Country Link
US (2) US20060057102A1 (es)
AR (2) AR050693A1 (es)
TW (2) TW200613552A (es)
WO (2) WO2006017853A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
TW200613552A (en) * 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
CA2608474C (en) 2005-05-17 2019-11-12 University Of Connecticut Compositions and methods for immunomodulation in an organism
CA2636111C (en) 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
EP1921452A1 (en) * 2006-11-08 2008-05-14 Medizinische Hochschule Hannover Method for the diagnosis of leukemia
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US20110020269A1 (en) * 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
WO2009002562A2 (en) 2007-06-27 2008-12-31 Marine Polymer Technologies, Inc. Complexes of il-15 and il-15ralpha and uses thereof
AU2010253863B2 (en) * 2009-05-28 2016-01-28 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
EP3135294B1 (en) 2009-08-14 2020-06-03 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Use of il-15-il-15 receptor heterodimers to treat lymphopenia
JP2016533332A (ja) * 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CN107001438A (zh) * 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
EP3350205A1 (en) 2015-09-16 2018-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
WO2017112528A2 (en) * 2015-12-21 2017-06-29 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
BR112019012570A8 (pt) * 2016-12-21 2023-01-24 Cephalon Inc Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
CN111432836A (zh) 2017-09-05 2020-07-17 转矩医疗股份有限公司 治疗性蛋白质组合物及其制备和使用方法
EP3758729A4 (en) * 2018-02-26 2021-11-17 Synthorx, Inc. IL-15 CONJUGATES AND THEIR USES
MX2021010670A (es) 2019-03-05 2021-11-12 Nkarta Inc Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
CA3136241A1 (en) 2019-05-20 2020-11-26 Ulrich Moebius Il-2/il-15r.beta.y agonist dosing regimens for treating cancer or infectious diseases
JP2023512452A (ja) * 2020-01-13 2023-03-27 ンカルタ・インコーポレイテッド Ｂｃｍａ指向性細胞免疫療法組成物および方法
IL302313A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of non-melanoma skin cancer
US20230390361A1 (en) 2020-10-26 2023-12-07 Cytune Pharma Il-2/il-15r-beta-gamma agonist for treating squamous cell carcinoma
AU2022299404A1 (en) 2021-06-23 2023-12-07 Cytune Pharma Interleukin 15 variants
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
CN113956346B (zh) * 2021-10-26 2024-03-01 西安龙腾景云生物科技有限公司 一种重组白介素-15变体
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
EP0927254B1 (en) * 1996-04-26 2005-06-22 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
TW200613552A (en) * 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
AU2005335217A1 (en) * 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of B cell proliferation by IL-15

Also Published As

Publication number Publication date
AR050693A1 (es) 2006-11-15
WO2006020849A3 (en) 2006-10-05
WO2006020849A2 (en) 2006-02-23
TW200619227A (en) 2006-06-16
WO2006017853A2 (en) 2006-02-16
TW200613552A (en) 2006-05-01
US20060057102A1 (en) 2006-03-16
WO2006017853A3 (en) 2007-01-04
US20060057680A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
AR050293A1 (es) Polipeptidos de interleuquina-15 mutante
MX2020009824A (es) Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
AR114445A1 (es) Conjugados de il-15, y sus usos
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
AR079338A1 (es) Variantes de proteasa de bacillus y acidos nucleicos que codifican dichas variantes
CO6231052A2 (es) Polipeptidos de factor vii modificados y usos de los mismos
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas
DK1654355T3 (da) Pseudomonas polypeptidvarianter med ikke-maltogen exoamylaseaktivitet og deres anvendelse til fremstilling af fødevarer
CY1111411T1 (el) Αναλογα του παρομοιου-με-την-γλυκαγονη-πεπτιδιου-2(glp-2)
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
ES2536974T3 (es) Péptidos de epítopos del receptor de EGF y usos de los mismos
ATE119941T1 (de) Subtilisin-analoge.
DE69333672D1 (de) Rekombinante lipase und alpha-amylase varianten
DK1237930T3 (da) Kimære amyloid-beta-peptider
PE20090682A1 (es) Secuencias peptidicas y composiciones
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
DE602006020562D1 (de) Hren dafür
AR070491A1 (es) Variante de enzima lipolitica con estabilidad aumentada y polinucleotidos que la codifican
ATE488526T1 (de) Chimärer impfstoff für haemophilus influenzae- induzierte infektion
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
WO2021216743A3 (en) Coronavirus vaccines, compositions, and methods related thereto
NZ605037A (en) Immunology treatment for biofilms
CL2021000883A1 (es) Composiciones de polipéptidos estabilizados con enlace disulfuro y métodos de uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal